Zymeworks/$ZYME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ticker
$ZYME
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
299
Website
Zymeworks Metrics
BasicAdvanced
$940M
-
-$1.50
1.17
-
Price and volume
Market cap
$940M
Beta
1.17
52-week high
$17.11
52-week low
$9.03
Average daily volume
472K
Financial strength
Current ratio
4.707
Quick ratio
4.453
Long term debt to equity
4.678
Total debt to equity
5.682
Profitability
EBITDA (TTM)
-99.293
Gross margin (TTM)
-49.38%
Net profit margin (TTM)
-121.73%
Operating margin (TTM)
-116.52%
Effective tax rate (TTM)
-6.07%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-13.89%
Return on equity (TTM)
-29.80%
Valuation
Price to revenue (TTM)
10.166
Price to book
2.69
Price to tangible book (TTM)
2.82
Price to free cash flow (TTM)
-12.09
Free cash flow yield (TTM)
-8.27%
Free cash flow per share (TTM)
-1.039
Growth
Revenue change (TTM)
85.05%
Earnings per share change (TTM)
-14.96%
3-year revenue growth (CAGR)
49.49%
3-year earnings per share growth (CAGR)
-32.86%
What the Analysts think about Zymeworks
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Bulls say / Bears say
Zymeworks' lead product, zanidatamab, received approval from China's NMPA for treating HER2-positive biliary tract cancer, expanding its market reach and potential revenue streams. (Zymeworks Press Release)
The company reported a significant increase in Q1 2025 revenue to $27.1 million, up from $10.0 million in Q1 2024, indicating strong financial growth. (Zymeworks Press Release)
Analysts at Lifesci Capital initiated coverage with an 'outperform' rating and a $30.00 price target, suggesting confidence in the company's future performance. (MarketBeat)
HC Wainwright reaffirmed a 'neutral' rating with a $12.00 price target, indicating potential concerns about the company's valuation or growth prospects. (MarketBeat)
Despite recent approvals, Zymeworks remains a clinical-stage company with ongoing expenses and no guarantee of future product success, posing financial risks. (Zymeworks Press Release)
The biotechnology sector is highly competitive, and Zymeworks faces challenges from larger, more established companies with greater resources. (Zymeworks Press Release)
Data summarised monthly by Lightyear AI. Last updated on 13 Jul 2025.
Zymeworks Financial Performance
Revenues and expenses
Zymeworks Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zymeworks stock?
Zymeworks (ZYME) has a market cap of $940M as of August 01, 2025.
What is the P/E ratio for Zymeworks stock?
The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of August 01, 2025.
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.